Is Nuvation Bio Inc. (NUVB) a Buy, Sell, or Hold?
NYSE : NUVB
Nuvation Bio Inc.
$6.33 USD
-$0.37 (-5.52%)
- Volume
- 3.93M
- Average Volume
- 6.5M
- Market Capitalization
- $2.2B
- P/E Ratio
- -14.91
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $9.75
- Year Low
- $2.18
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.44
Company Overview
NYSE
David T. Hung
Biotechnology
Healthcare
NUVB
307
US
USD
Liquidity Metrics
0.03
7.44
7.24
1.58
0.00
Sales & Valuation
$62.9M
15.36
6.88
-17.43
-0.36
Profitability
-$0.6
-$204.63M
-102.06%
-102.06%
-44.10%
-23.92%
P/E Metrics
-14.91
-0.11
-0.11
Analyst Price Target & Rating
$20.00
$21.00
$19.00
2/5
10 Analysts
-68.35%
Financial Health Scores
2.78
3/9
$512.01M
$610.24M
$290.68M
-$131.69M
Key Metrics (TTM)
$2.08B
14.56
-16.05
7.44
-44.10%
-27.90%
-6.64%
-5.74%
-135 days
Company Executives
| Name | Title |
|---|---|
| David Liu | Chief Medical Officer |
| Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer |
| Robert DeVita | Vice President of Corporate Development & Investor Relations |
| Gary Hattersley | Chief Scientific Officer |
| David T. Hung | Founder, President, Chief Executive Officer & Chairman |
| Kerry A. Wentworth | Chief Regulatory Officer |
| David C. Hanley | Chief Technical Operations Officer |
| Stacy Markel | Chief People Officer |
| Stephen Dang | Chief Legal Officer & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Nuvation Bio Inc. (NYSE:NUVB) Stock
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a pol ... y ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-30 11:06:11
Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2026-07-29 10:56:13
The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2026-07-22 16:05:00
NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2026.
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
2026-07-21 11:10:25
Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2026-07-20 08:00:00
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S. New Phase 2 study to evaluate safusidenib in patients whose glioma has progressed following treatment with vorasidenib in U.S. NEW YORK, July 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced updated positive long-term follow-up data from the Phase 2 (J201) study of safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma. With an additional year of follow-up, responses to safusidenib increased and further deepened, and its safety profile remained consistent and manageable.
2026-07-06 17:09:00
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the underwriters have exercised in full their over-allotment option (the "Greenshoe Exercise") to purchase an additional $37.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2032 (the "Notes"). The aggregate principal amount of Notes sold in the offering was $287.5 million, inclusive of the $37.5 million aggregate principal amount of Notes issued pursuant to the Greenshoe Exercise.
2026-06-29 19:19:05
According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026. This transaction represented 79.32% of Markel Stacy's direct Class A holdings, reducing the direct position to 32,591 shares, though she also retains significant exposure through stock options.
2026-06-29 08:00:00
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
Frequently Asked Questions
-
What is the current Nuvation Bio Inc. (NUVB) stock price?
-
Nuvation Bio Inc.(NYSE:NUVB) stock price is $6.33 in the last trading session. During the trading session, NUVB stock reached the peak price of $9.75 while $2.18 was the lowest point it dropped to. The percentage change in NUVB stock occurred in the recent session was --5.52% while the dollar amount for the price change in NUVB stock was -$0.37.
-
NUVB's industry and sector of operation?
-
The NYSE listed NUVB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NUVB?
-
David Liu | Chief Medical Officer
Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer
Philippe Sauvage | Chief Financial Officer & Principal Financial Officer
Robert DeVita | Vice President of Corporate Development & Investor Relations
Gary Hattersley | Chief Scientific Officer -
How many employees does NUVB have?
-
Number of NUVB employees currently stands at 307. NUVB operates from 1500 Broadway, New York City, NY 10036, US.
-
Link for NUVB official website?
-
Official Website of NUVB is: https://www.nuvationbio.com
-
How do I contact NUVB?
-
NUVB could be contacted at phone #332 208 6102 and can also be accessed through its website. NUVB operates from 1500 Broadway, New York City, NY 10036, US.
-
How many shares of NUVB are traded daily?
-
The average number of NUVB shares traded daily for last 3 months was 6.5M.
-
What is the market cap of NUVB currently?
-
The market value of NUVB currently stands at $2.2B with its latest stock price at $6.33